Oncology and Hematology Expertise

Ronél Steyn, Head of Hemato-Oncology Business Unit

  • 26 years’ of experience in the pharma industry, of which the last 22 are in clinical research
  • Primary focus on global oncology and hematology portfolio management
  • Gobal oncology and hematology operational oversight and leadership
  • Experience primarily within oncology and hematology therapeutic areas across all phases of trials incl. immuno-oncology trials and complex early phase basket trials

Karl Kendall, Senior Director Project Management US, Hemato-Oncology Business Unit

  • Over 20 years of clinical research experience, 8 of which focused on oncology
  • Portfolio management/oversight of suites of over 100 PhI-III hemato-oncology studies
  • Experienced in a variety of indications including NSCLC, breast cancer, prostate cancer, solid tumors, HPV/cervical, and malignant hematology studies for large pharma as well as smaller to mid-sized biotech sponsors and CRO partnerships

Mark Clegg, Senior Director Project Management, Hemato-Oncology Business Unit

  • +25 years' experience in clinical research
  • Degree in pharmacy and PhD in pharmacology
  • Experienced in direct project management of hematological malignancies and solid tumors, primarily in Phase I & II, as well as global operational oversight and leadership of project managers running a wide range of oncology studies
  • Extensive knowledge of clinical research processes, project management methodology, industry regulations and guidelines

External Medical Advisors

Dr. Vincent Valentí

  • Medical Scientific Advisor with TFS since 2006
  • Active in research for cancer treatment for +15 years and frequent presenter at scientific congresses
  • Head of the Clinical Oncology at the Hospital Santa Tecla in Tarragona, Spain
  • Providing medical expertise on Oncology to TFS project teams, medical training in for TFS’s employees and, represents TFS in customer meetings
  • Provides support in the preparation of protocols and manuscripts for several clinical and non-interventional studies



Read here: First in Man Solid Tumor Oncology